NasdaqGS - Nasdaq Real Time Price USD

DexCom, Inc. (DXCM)

134.24

+2.72

(+2.07%)

As of 10:53 AM EDT. Market Open.

Boston Scientific, Dexcom and Edwards next as earnings season rolls on

J.P. Morgan analysts expect this week’s results to be “very good” following reports from J&J, Abbott and Intuitive Surgical.

MedTech Dive 4 hours ago

BSX

EW

MDT
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Zacks yesterday

DXCM
+2.07%
Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom

Vertiv, Align Technology and DexCom are part of the Zacks Investment Ideas article.

Zacks yesterday

DXCM
+2.07%
VRT

^GSPC
DexCom Insiders Sold US$18m Of Shares Suggesting Hesitancy

Many DexCom, Inc. ( NASDAQ:DXCM ) insiders ditched their stock over the past year, which may be of interest to the...

Simply Wall St. yesterday

DXCM
+2.07%
Even IBD 50 Medical Products Stocks Don't All Look Healthy In This Sick Market

Dexcom stock reversed on Friday and fell below a buy point. But one of these medical stocks is still in a buy zone.

Investor's Business Daily 3 days ago

DXCM
+2.07%
Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week

Dexcom stock is in a buy zone ahead of earnings next week. Shares rallied after the company launched a prescription-free glucose monitoring device.

Investor's Business Daily 4 days ago

DXCM
+2.07%
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback

Long-term investors are often well-served to buy stocks amid bouts of weakness.

Zacks 4 days ago

DXCM
+2.07%
VRT
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Zacks 5 days ago

DXCM
+2.07%
EVP Strategy and Corporate Dev Matthew Dolan Sells Shares of DexCom Inc (DXCM)

EVP Strategy and Corporate Development Matthew Dolan has sold 1,990 shares of DexCom Inc (NASDAQ:DXCM) on April 15, 2024, according to a recent SEC filing.

GuruFocus.com 6 days ago

DXCM
+2.07%
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS

Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.

Zacks 7 days ago

EW

DXCM
+2.07%
STE
14 Best 52-Week High Stocks To Invest In Now

This article delves into the examination of the 14 best 52-week high stocks to buy now. To explore more such companies that meet comparable criteria, go directly to 5 Best 52-Week High Stocks To Buy Now. The outlook for 2024 is positive for the economy and the stock market. Market conditions improved significantly in Q4 […]

Insider Monkey 7 days ago

LEN-B

CI

BSX
DexCom (DXCM) Stock Moves -1.16%: What You Should Know

In the latest trading session, DexCom (DXCM) closed at $134.56, marking a -1.16% move from the previous day.

Zacks 7 days ago

DXCM
+2.07%
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.

Zacks 7 days ago

EW

DXCM
+2.07%
STE
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management

DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.

Zacks 7 days ago

DXCM
+2.07%
CAH

DVA
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit

Metabolic health is all the rage, helped by the advent of weight-loss drugs and continuous glucose monitors. Can they change disease forever?

Investor's Business Daily 11 days ago

ABT

DXCM
+2.07%
MDT
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Zacks 12 days ago

DXCM
+2.07%
ANIK
Insider Sell: DexCom Inc (DXCM) President, CEO and Chairman Kevin Sayer Sells 49,633 Shares

On April 8, 2024, Kevin Sayer, President, CEO and Chairman of DexCom Inc (NASDAQ:DXCM), sold 49,633 shares of the company.

GuruFocus.com 12 days ago

DXCM
+2.07%
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In

The latest employment figures saw indices rise. However, losses earlier in the week persist as investors remain cautious of the Fed’s stance on interest rate adjustments. Amid this climate, it’s essential to highlight a few potential Nasdaq stocks to sell. They could represent a shift from the buoyant sentiment a month ago when the Nasdaq and broader markets reached successive record highs. While returns have been strong year-to-date (YTD), some analysts argue that exuberance may be fading as th

InvestorPlace 12 days ago

AMD

DXCM
+2.07%
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

The burgeoning interest in obesity drugs, particularly GLP-1 products such as Ozempic, Saxenda, and Mounjaro, marks a significant shift in the global approach to managing obesity. In this article, we look at three obesity drug stocks investors should consider. Shares of the companies producing these drugs soared in 2023 as demand outstripped supply and projections suggesting a market growth to $150 billion annually within the next decade. The surge is driven by the drugs’ effectiveness not only

InvestorPlace 12 days ago

LLY

NVO

DXCM
+2.07%
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema

MarketWatch 13 days ago

NVO

VRTX
+1.51%
LLY

Performance Overview

Return	DXCM	S&P 500
YTD	+8.18%	+6.14%
1-Year	+8.49%	+22.48%
3-Year	+30.84%	+22.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

DexCom, Inc. (DXCM)

Boston Scientific, Dexcom and Edwards next as earnings season rolls on

Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom

DexCom Insiders Sold US$18m Of Shares Suggesting Hesitancy

Even IBD 50 Medical Products Stocks Don't All Look Healthy In This Sick Market

Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week

3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

EVP Strategy and Corporate Dev Matthew Dolan Sells Shares of DexCom Inc (DXCM)

Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS

14 Best 52-Week High Stocks To Invest In Now

DexCom (DXCM) Stock Moves -1.16%: What You Should Know

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management

Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Insider Sell: DexCom Inc (DXCM) President, CEO and Chairman Kevin Sayer Sells 49,633 Shares

Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

Performance Overview